Edwards Lifesciences Corp. (EW) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153523,
    "name": "Edwards Lifesciences Corp.",
    "stock_name": "Edwards Lifesciences Corp.",
    "full_name": "Edwards Lifesciences Corp.",
    "name_url": "stocks-analysis/edwards-lifesciences-corp",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "85.78",
    "chg": 1.8,
    "chgp": "2.14%",
    "dir": 1,
    "prev_price": "83.98",
    "mcapval": "48,454.86",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US28176E1082",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.39 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/edwards-lifesciences-corp-1153523-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Edwards Lifesciences Corp. Hits New 52-Week High at $87.09",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/edwards-lifesciences-corp-hits-new-52-week-high-at-8709-3667276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EdwardsLifescie_priceRelatedfactors_3667276.png",
        "date": "2025-11-03 17:05:18",
        "description": "Edwards Lifesciences Corp. achieved a new 52-week high of USD 87.09 on October 31, 2025, despite a one-year performance decline. With a market cap of USD 48,455 million, the company shows strong financial metrics, including a P/E ratio of 30.00 and a return on equity of 14.74%."
      },
      {
        "title": "Edwards Lifesciences Corp. Hits New 52-Week High at $84.66",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/edwards-lifesciences-corp-hits-new-52-week-high-at-8466-3659098",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EdwardsLifescie_priceRelatedfactors_3659098.png",
        "date": "2025-10-30 18:26:48",
        "description": "Edwards Lifesciences Corp. achieved a new 52-week high of USD 84.66 on October 29, 2025, despite a one-year performance decline of 3.96%. With a market cap of USD 48,455 million, the company has a P/E ratio of 30.00 and a return on equity of 14.74%."
      },
      {
        "title": "Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/edwards-lifesciences-corp-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-stock-price-increase-3651991",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EdwardsLifescie_technicaldot_3651991.png",
        "date": "2025-10-28 15:13:54",
        "description": "Edwards Lifesciences Corp. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $80.82, reflecting a notable increase. Technical indicators show mixed performance, with varying trends across different timeframes. The company's returns have lagged behind the S&P 500 over longer periods."
      },
      {
        "title": "Is Edwards Lifesciences Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-edwards-lifesciences-corp-technically-bullish-or-bearish-3651311",
        "imagepath": "",
        "date": "2025-10-28 11:40:13",
        "description": "As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST show a mildly bearish trend. Monthly indicators present a mixed view with the MACD and KST mildly bullish, but Bollinger Bands and Dow Theory both bearish on a monthly basis. \n\nIn terms of performance, the stock has returned 1.93% over the past month, which underperforms the S&P 500's 2.32% return, and year-to-date, it has gained 2.80% compared to the S&P 500's 15.47%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across various indicators...."
      },
      {
        "title": "Is Edwards Lifesciences Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-edwards-lifesciences-corp-technically-bullish-or-bearish-3647765",
        "imagepath": "",
        "date": "2025-10-27 11:51:21",
        "description": "As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, contrasting with the monthly MACD and KST, which are mildly bullish. Overall, the indicators present a mixed picture, with the weekly and monthly Bollinger Bands showing bearish signals. \n\nIn terms of performance, the stock has returned 1.93% over the past month, underperforming the S&P 500's 2.32%, and has a year-to-date return of 2.80%, significantly lagging behind the S&P 500's 15.47%. This suggests a bearish trend over longer periods, particularly with a 3-year return of -10.38% compared to the S&P 500's 78.85%. The current technical stance is mildly bullish, but the strength is tempered by bearish signals in several indicators...."
      },
      {
        "title": "Is Edwards Lifesciences Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-edwards-lifesciences-corp-technically-bullish-or-bearish-3646298",
        "imagepath": "",
        "date": "2025-10-26 11:26:00",
        "description": "As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, creating a mixed signal. The monthly MACD and KST are mildly bullish, suggesting some strength in the longer term. However, the Bollinger Bands and Dow Theory show mildly bearish signals on both weekly and monthly time frames. \n\nIn terms of performance, the stock has returned 1.96% over the past week, slightly outperforming the S&P 500's 1.92%, but it lags behind the benchmark in the longer term, with a year-to-date return of 2.80% compared to the S&P 500's 15.47%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from various indicators...."
      },
      {
        "title": "Is Edwards Lifesciences Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-edwards-lifesciences-corp-technically-bullish-or-bearish-3545782",
        "imagepath": "",
        "date": "2025-09-20 19:18:32",
        "description": "As of 3 September 2025, the technical trend for Edwards Lifesciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while weekly indicators such as MACD, RSI, and Dow Theory show mild bearishness. Monthly metrics present a mixed picture with mild bullishness in MACD and KST, but bearish signals in Bollinger Bands and OBV. \n\nIn terms of multi-period returns, the stock has underperformed compared to the S&P 500 across various time frames, particularly over the last 1W and 1M, where it declined by -4.44% and -4.79%, respectively, while the S&P 500 gained 1.05% and 2.33%. Over the longer term, the stock has also lagged, with a -20.14% return over 3 years compared to the S&P 500's 70.41%...."
      },
      {
        "title": "Is Edwards Lifesciences Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-edwards-lifesciences-corp-overvalued-or-undervalued-3542459",
        "imagepath": "",
        "date": "2025-09-20 17:53:15",
        "description": "As of 24 July 2025, the valuation grade for Edwards Lifesciences Corp. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on key metrics, including a P/E ratio of 30, a Price to Book Value of 4.62, and an EV to EBITDA ratio of 26.46. In comparison to peers, Agilent Technologies, Inc. has a more favorable P/E ratio of 27.42, while DexCom, Inc. is also considered expensive with a P/E of 53.65.\n\nThe recent stock performance further supports this valuation narrative, as Edwards Lifesciences has underperformed against the S&P 500 over multiple periods, including a -20.14% return over three years compared to the S&P 500's 70.41%. This trend highlights the challenges the company faces in delivering shareholder value relative to broader market performance...."
      }
    ],
    "total": 13,
    "sid": "1153523",
    "stock_news_url": "https://www.marketsmojo.com/news/edwards-lifesciences-corp-1153523"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Edwards Lifesciences Corp. Hits New 52-Week High at $87.09

2025-11-03 17:05:18

Edwards Lifesciences Corp. achieved a new 52-week high of USD 87.09 on October 31, 2025, despite a one-year performance decline. With a market cap of USD 48,455 million, the company shows strong financial metrics, including a P/E ratio of 30.00 and a return on equity of 14.74%.

Edwards Lifesciences Corp. Hits New 52-Week High at $84.66

2025-10-30 18:26:48

Edwards Lifesciences Corp. achieved a new 52-week high of USD 84.66 on October 29, 2025, despite a one-year performance decline of 3.96%. With a market cap of USD 48,455 million, the company has a P/E ratio of 30.00 and a return on equity of 14.74%.

Edwards Lifesciences Corp. Experiences Evaluation Revision Amid Mixed Market Performance Indicators

2025-10-28 15:13:54

Edwards Lifesciences Corp. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $80.82, reflecting a notable increase. Technical indicators show mixed performance, with varying trends across different timeframes. The company's returns have lagged behind the S&P 500 over longer periods.

Is Edwards Lifesciences Corp. technically bullish or bearish?

2025-10-28 11:40:13

As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST show a mildly bearish trend. Monthly indicators present a mixed view with the MACD and KST mildly bullish, but Bollinger Bands and Dow Theory both bearish on a monthly basis. In terms of performance, the stock has returned 1.93% over the past month, which underperforms the S&P 500's 2.32% return, and year-to-date, it has gained 2.80% compared to the S&P 500's 15.47%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals across various indicators....

Is Edwards Lifesciences Corp. technically bullish or bearish?

2025-10-27 11:51:21

As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, contrasting with the monthly MACD and KST, which are mildly bullish. Overall, the indicators present a mixed picture, with the weekly and monthly Bollinger Bands showing bearish signals. In terms of performance, the stock has returned 1.93% over the past month, underperforming the S&P 500's 2.32%, and has a year-to-date return of 2.80%, significantly lagging behind the S&P 500's 15.47%. This suggests a bearish trend over longer periods, particularly with a 3-year return of -10.38% compared to the S&P 500's 78.85%. The current technical stance is mildly bullish, but the strength is tempered by bearish signals in several indicators....

Is Edwards Lifesciences Corp. technically bullish or bearish?

2025-10-26 11:26:00

As of 24 October 2025, the technical trend for Edwards Lifesciences Corp. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, creating a mixed signal. The monthly MACD and KST are mildly bullish, suggesting some strength in the longer term. However, the Bollinger Bands and Dow Theory show mildly bearish signals on both weekly and monthly time frames. In terms of performance, the stock has returned 1.96% over the past week, slightly outperforming the S&P 500's 1.92%, but it lags behind the benchmark in the longer term, with a year-to-date return of 2.80% compared to the S&P 500's 15.47%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from various indicators....

Is Edwards Lifesciences Corp. technically bullish or bearish?

2025-09-20 19:18:32

As of 3 September 2025, the technical trend for Edwards Lifesciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while weekly indicators such as MACD, RSI, and Dow Theory show mild bearishness. Monthly metrics present a mixed picture with mild bullishness in MACD and KST, but bearish signals in Bollinger Bands and OBV. In terms of multi-period returns, the stock has underperformed compared to the S&P 500 across various time frames, particularly over the last 1W and 1M, where it declined by -4.44% and -4.79%, respectively, while the S&P 500 gained 1.05% and 2.33%. Over the longer term, the stock has also lagged, with a -20.14% return over 3 years compared to the S&P 500's 70.41%....

Is Edwards Lifesciences Corp. overvalued or undervalued?

2025-09-20 17:53:15

As of 24 July 2025, the valuation grade for Edwards Lifesciences Corp. has moved from fair to expensive, indicating a shift towards overvaluation. The company appears overvalued based on key metrics, including a P/E ratio of 30, a Price to Book Value of 4.62, and an EV to EBITDA ratio of 26.46. In comparison to peers, Agilent Technologies, Inc. has a more favorable P/E ratio of 27.42, while DexCom, Inc. is also considered expensive with a P/E of 53.65. The recent stock performance further supports this valuation narrative, as Edwards Lifesciences has underperformed against the S&P 500 over multiple periods, including a -20.14% return over three years compared to the S&P 500's 70.41%. This trend highlights the challenges the company faces in delivering shareholder value relative to broader market performance....

View All News